Silexion Therapeutics Ltd. (SLXN) 10-Year Financial Performance & Capital Metrics

SLXN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutSilexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.Show more

Revenue $0
EBITDA -$13M -170.6%
Net Income -$16M -232.7%
EPS (Diluted) -2.64 +40.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -241.75 +53.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM54.15%

EPS CAGR

10Y-

5Y-

3Y-

TTM259.74%

ROCE

10Y Avg-267.64%

5Y Avg-267.64%

3Y Avg-380.23%

Latest-1047.58%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	195.86K	943.93K	3.86M	4.68M	12.57M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	195.86K	943.93K	577K	928K	6.73M
SG&A % of Revenue	-	-	-	-	-
Research & Development	0	0	3.23M	3.71M	5.82M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	57K	45K	25K
Operating Income+	-195.86K	-943.93K	-3.86M	-4.68M	-12.57M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-3.82%	-3.09%	-0.21%	-1.69%
EBITDA+	-195.86K	-755K	-3.8M	-4.64M	-12.55M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-2.85%	-4.04%	-0.22%	-1.71%
D&A (Non-Cash Add-back)	0	0	57K	45K	25K
EBIT	-195.86K	-755K	-3.86M	-4.68M	-16.5M
Net Interest Income+	0	6.37K	29K	144K	-51K
Interest Income	0	6.37K	114K	153K	1K
Interest Expense	0	0	85K	9K	52K
Other Income/Expense	0	188.72K	396K	-395K	-3.94M
Pretax Income+	-195.86K	-755.22K	-3.46M	-5.08M	-16.51M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	24K	32K	10K
Effective Tax Rate %	1%	1%	0.93%	0.97%	1%
Net Income+	-195.86K	-755.22K	-3.21M	-4.94M	-16.44M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-2.86%	-3.26%	-0.54%	-2.33%
Net Income (Continuing)	-195.86K	-755.22K	-3.49M	-5.11M	-16.52M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	3.59M	3.42M	0
EPS (Diluted)+	-0.01	-0.05	0.03	-4.42	-2.64
EPS Growth %	-	-2.85%	1.76%	-127.65%	0.4%
EPS (Basic)	-0.01	-0.05	0.03	-4.42	-2.64
Diluted Shares Outstanding	16.51M	16.51M	16.73M	1.12M	6.24M
Basic Shares Outstanding	16.51M	16.51M	16.73M	1.12M	6.24M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	51.7K	407.8K	8.84M	4.98M	2.25M
Cash & Short-Term Investments	51.7K	38.94K	8.26M	4.59M	1.19M
Cash Only	51.7K	38.94K	8.26M	4.59M	1.19M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	67K	49K	97K
Total Non-Current Assets+	77.7K	115.01M	494K	277K	613K
Property, Plant & Equipment	0	0	464K	247K	560K
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	115.01M	0	0	0
Other Non-Current Assets	77.7K	0	30K	30K	53K
Total Assets+	129.4K	115.41M	9.33M	5.26M	2.86M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	890.92%	-0.92%	-0.44%	-0.46%
Total Current Liabilities+	29.4K	348.58K	1.61M	2.2M	3.52M
Accounts Payable	0	0	240K	319K	929K
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	0	0	0	0	1M
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	29.4K	348.58K	256K	407K	644K
Current Ratio	1.76x	1.17x	5.49x	2.27x	0.64x
Quick Ratio	1.76x	1.17x	5.49x	2.27x	0.64x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	269.99K	160.34K	14.8M	15.12M	3.33M
Long-Term Debt	0	0	0	0	2.96M
Capital Lease Obligations	0	0	156K	59K	368K
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	269.99K	160.34K	14.65M	15.06M	0
Total Liabilities	299.39K	508.92K	16.41M	17.31M	6.85M
Total Debt+	0	0	271K	171K	4.49M
Net Debt	-51.7K	-38.94K	-7.99M	-4.42M	3.3M
Debt / Equity	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-45.41x	-520.11x	-241.75x
Total Equity+	-169.99K	114.91M	-7.08M	-12.06M	-3.99M
Equity Growth %	-	676.95%	-1.06%	-0.7%	0.67%
Book Value per Share	-0.01	6.96	-0.42	-10.79	-0.64
Total Shareholders' Equity	-169.99K	114.91M	-10.66M	-15.48M	-3.99M
Common Stock	298	115M	1K	1K	2K
Retained Earnings	-195.86K	-951.08K	-21.87M	-26.81M	-43.25M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	3.59M	3.42M	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-75K	-1.41M	-3.33M	-4.53M	-8.4M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-17.76%	-1.37%	-0.36%	-0.85%
Net Income	-195.86K	-755.22K	-3.49M	-5.11M	-16.52M
Depreciation & Amortization	0	0	57K	45K	25K
Stock-Based Compensation	0	0	125K	130K	5.86M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	-182.34K	-268K	317K	3.82M
Working Capital Changes	120.86K	-469.68K	239K	87K	-1.58M
Change in Receivables	0	0	-40K	18K	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	-38K	79K	610K
Cash from Investing+	0	0	-524K	573K	-22K
Capital Expenditures	0	0	-40K	-12K	-22K
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	78K	0
Cash from Financing+	126.7K	116.4M	2.75M	522K	5.1M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	-2.55M	3K	0	2.3M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-75K	-1.41M	-3.38M	-4.54M	-8.42M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-17.76%	-1.4%	-0.35%	-0.85%
FCF per Share	-0.00	-0.09	-0.20	-4.06	-1.35
FCF Conversion (FCF/Net Income)	0.38x	1.86x	1.04x	0.92x	0.51x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-1.32%	-5.96%	-	-
Return on Invested Capital (ROIC)	-	-1.23%	-5.8%	-	-
Interest Coverage	-	-	-45.41x	-520.11x	-241.75x
FCF Conversion	0.38x	1.86x	1.04x	0.92x	0.51x

Frequently Asked Questions

Growth & Financials

Silexion Therapeutics Ltd. (SLXN) grew revenue by 0.0% over the past year. Growth has been modest.

Silexion Therapeutics Ltd. (SLXN) reported a net loss of $7.5M for fiscal year 2024.

Dividend & Returns

Silexion Therapeutics Ltd. (SLXN) had negative free cash flow of $10.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener